APOL1 risk variants and death among African American hemodialysis patients: survival of the fittest?
APOL1 risk variants and death among African American hemodialysis patients: survival of the fittest?
复制标题
非裔美国血液透析患者的 APOL1 风险变异和死亡：适者生存？
DOI：
10.1016/j.kint.2016.03.024
复制
发表时间：
2016
影响因子：
19.6
通讯作者：
Estrella,MichelleM
中科院分区：
文献类型：
--
作者：
Chen,TeresaK;Estrella,MichelleM
最近的研究集中在apol1风险变异与肾脏疾病以外的结果，包括心血管疾病和死亡率的关系。马和他的同事们现在对这一不断发展但相互矛盾的工作进行了扩展。他们对非裔美国血液透析患者的流行队列分析表明，风险变异与非糖尿病患者的生存获益有关。这是否仅仅反映了携带两种风险变异的人在血液透析开始时的健康状况，或者这些变异是否真的赋予了生存优势尚不清楚。
Recent studies have focused on associations of theAPOL1risk variants with outcomes beyond kidney disease, including cardiovascular disease and mortality. Ma and colleagues now expand on this growing but contradicting body of work. Their analysis of a prevalent cohort of African American hemodialysis patients shows that the risk variants are associated with a survival benefit among nondiabetics. Whether this simply reflects a healthier status at hemodialysis initiation among those carrying 2 risk variants or whether these variants truly confer a survival advantage is unclear.